Paper Details

  1. Home
  2. Paper Details

An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.

Author: MisraAnoop, SinghAkriti, SinghAwadhesh Kumar, SinghRitu

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Molnupiravir is an oral antiviral drug that has recently received emergency use authorization (EUA) for the treatment of COVID-19 in the USA, UK, and India. This systematic review found that molnupiravir could be a useful agent in non-pregnant unvaccinated adults with COVID-19 who are at increased risk of severity including hospitalization. It is effective only when used within 5 days of onset of symptoms. A 5-day course seems to be safe without any obvious short-term side effects.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND AIMS: Molnupiravir is a newer oral antiviral drug that has recently received emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on our previous systematic review to provide practical clinical guideline for using molnupiravir in patients with COVID-19. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755553/

データ提供：米国国立医学図書館（NLM）

Molnupiravir: A New Weapon in the Fight Against COVID-19

The COVID-19 pandemic has spurred the development of various treatments and interventions, including antiviral medications. This research provides an updated guideline on the use of molnupiravir, a newer oral antiviral drug that has recently received emergency use authorization for treating COVID-19. The study examines the efficacy and safety of molnupiravir, comparing it to other authorized agents for treating COVID-19. The findings offer valuable insights into the potential role of molnupiravir in managing this disease.

Molnupiravir's Efficacy: A Promising Candidate

The study revealed that molnupiravir significantly reduced the composite risk of hospitalization or death in non-hospitalized COVID-19 patients, particularly when administered within five days of symptom onset. While the relative risk reduction was less pronounced, the number needed to treat to prevent one death or one hospitalization or death composite was competitive with other authorized agents.

Considerations for Using Molnupiravir

The study highlights key considerations for using molnupiravir, including the need for early treatment within the first five days of symptom onset and its suitability for unvaccinated adults at increased risk of severe COVID-19. The study also suggests that molnupiravir appears to be safe, with no obvious short-term side effects observed. However, it's important to note that further research is needed to fully understand its long-term effects and potential interactions with other medications.

Dr.Camel's Conclusion

This research is like a caravan of hope traversing the desert of COVID-19. Molnupiravir emerges as a promising new antiviral agent, offering a potential weapon in the fight against this challenging disease. However, it's crucial to remember that the journey through this pandemic is ongoing. Continued research and careful evaluation are essential to ensure the safe and effective use of molnupiravir and other potential treatments, ultimately guiding us towards a healthier future.

Date :
  1. Date Completed 2022-03-16
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

35051686

DOI: Digital Object Identifier

PMC8755553

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.